First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

Purpose: Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribulin may offer a more tolerable yet effective combi...

Full description

Bibliographic Details
Main Authors: Anne-Claire Hardy-Bessard, Fabien Brocard, Florian Clatot, Alain Lortholary, Benoît You, Julien Grenier, Jérôme Martin-Babau, Brigitte Lucas, Jérôme Meunier, Jean-Marc Ferrero, Aude-Marie Savoye, Adina Marti, Raymond Despax, Isabelle Moullet, George Emile
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Bevacizumab
Eribulin
Metastatic breast cancer
Combination therapy
Neuropathy
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301892

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301892

Similar Items